ENGN
ENGENE THERAP (ENGN)
NASDAQ
$1.70+$0.01 (+0.59%)
Price as of Jun 23, 2026 6:13 PM EDT
  • $113.2M
    Market Cap
  • -44.04%
    1-Year Change
  • Biotechnology
    Industry
Annual
Quarterly
10/31/2025
10/31/2024
10/31/2023
Income Statement
Total Operating Revenue
N/A
N/A
N/A
N/A
N/A
N/A
Cost of Revenue
N/A
N/A
N/A
N/A
N/A
N/A
Gross Profit
0
N/A
0
N/A
0
N/A
Sales and Marketing Expense
N/A
N/A
N/A
N/A
N/A
N/A
Research and Development Expense
-94.5M
+146.59%
-38.3M
+132.80%
-16.5M
N/A
Depreciation and Amortization Expense
509,000
+57.59%
323,000
+84.57%
175,000
N/A
Total Operating Expenses
123.2M
+97.71%
62.3M
+139.05%
26.1M
N/A
Operating Profit
-123.2M
+97.71%
-62.3M
+139.05%
-26.1M
N/A
Interest Income
9.4M
-9.48%
10.4M
+832.23%
1.1M
N/A
Interest Expense
-2.4M
+9.09%
-2.2M
-55.58%
-5.0M
N/A
Interest Income and Expense and Net
7.0M
-14.45%
8.2M
+314.10%
-3.8M
N/A
Total Nonoperating Income and Expense
5.9M
-17.84%
7.1M
+109.66%
-73.8M
N/A
Income before Taxes
-117.3M
+112.65%
-55.2M
-44.78%
-99.9M
N/A
Income Taxes
0
+100.00%
-19,000
-211.76%
17,000
N/A
Extraordinary Items
N/A
N/A
N/A
N/A
N/A
N/A
Net Income
-117.3M
+112.73%
-55.1M
-44.81%
-99.9M
N/A
Net Income from Continuing Operations Applicable to Common
-117.3M
+112.73%
-55.1M
-47.35%
-104.7M
N/A
Basic EPS and Net Income
2.29
+56.85%
1.46
-99.03%
151.22
N/A
Diluted EPS and Net Income
2.29
+56.85%
1.46
-99.03%
151.22
N/A
Basic Weighted Average Shares
51.1M
+35.30%
37.8M
+5,355.08%
692,609
N/A
Diluted Weighted Average Shares
51.1M
+35.30%
37.8M
+5,355.08%
692,609
N/A
Balance Sheet
Cash and Cash Equivalents
50.2M
-71.01%
173.0M
+112.22%
81.5M
N/A
Short-Term Investments
143.6M
+119.79%
65.3M
N/A
N/A
N/A
Cash and Cash Equivalents and Short-Term Investments
193.7M
-18.71%
238.3M
+192.36%
81.5M
N/A
Total Current Assets
201.4M
-18.58%
247.4M
+189.52%
85.4M
N/A
Accumulated Depreciation
2.1M
+30.62%
1.6M
-6.77%
1.7M
N/A
Property and Plant and Equipment and Net
2.5M
+111.89%
1.2M
+98.47%
589,000
N/A
Total Long-Term Assets
1.4M
-0.87%
1.4M
+47.74%
930,000
N/A
Total Assets
221.5M
-28.83%
311.2M
+257.84%
87.0M
N/A
Income Taxes Payable
19,000
-51.28%
39,000
0.00%
39,000
N/A
Total Short-Term Debt
8.0M
+1,044.78%
699,000
+24.38%
562,000
N/A
Total Current Liabilities
32.0M
+118.12%
14.7M
+178.89%
5.3M
N/A
Total Long-Term Debt
15.3M
-31.81%
22.5M
-15.58%
26.6M
N/A
Total Long-Term Liabilities
21.8M
-8.87%
23.9M
+15.62%
20.7M
N/A
Total Liabilities
53.8M
+39.41%
38.6M
+166.43%
14.5M
N/A
Retained Earnings
-372.0M
+46.05%
-254.7M
+27.63%
-199.6M
N/A
Total Stockholders Equity
167.7M
-38.48%
272.6M
+276.09%
72.5M
N/A
Total Shares Outstanding
52.0M
+2.04%
51.0M
+119.75%
23.2M
N/A
Cash Flow
Cash from Operating Activities
-99.2M
+105.54%
-48.3M
+95.13%
-24.7M
N/A
Capital Expenditures
1.5M
+60.54%
925,000
+190.88%
318,000
N/A
Cash from Investing Activities
-25.1M
-80.04%
-126.0M
+39,507.86%
-318,000
N/A
Dividends Paid
N/A
N/A
0
N/A
0
N/A
Cash from Financing Activities
1.5M
-99.43%
265.7M
+208.44%
86.1M
N/A
Financials Ratio
Gross Margin
N/A
N/A
N/A
N/A
N/A
N/A
Operating Margin
N/A
N/A
N/A
N/A
N/A
N/A
Return on Assets
-44.05%
+59.01%
-27.70%
N/A
N/A
N/A
Return on Equity
-53.28%
+66.72%
-31.96%
N/A
N/A
N/A
Revenue Growth
N/A
N/A
N/A
N/A
N/A
N/A
Current Ratio
6.30
-62.67%
16.87
N/A
N/A
N/A
Cash Ratio
1.57
-86.71%
11.80
N/A
N/A
N/A
Debt-to-Equity Ratio
0.14
+63.65%
0.09
N/A
N/A
N/A
Debt-to-Assets Ratio
0.11
+41.34%
0.07
N/A
N/A
N/A

Earnings & Revenue History

Debt-to-Assets

Cash Flow